Bakker W W, Roskam G, Hardonk M J, Vos J T, Bleumink E
Br J Exp Pathol. 1985 Feb;66(1):47-55.
Fractions of normal rat serum were purified using gel chromatography and their molecular weights were analysed using gradient polyacrylamide gel electrophoresis (PAGE). The fractions were tested for their capacity to affect in vitro glomerular polyanion (GPA) in rat kidney tissue whereas their vascular enhancing capacity in vivo after intradermal injection into the rat skin was analysed. GPA impairment in vitro was estimated after incubation of the fractions with tissue sections for 2 h at 37 degrees C and subsequent staining for sialoproteins with colloidal iron. Enhanced vascular responses were assayed using a standard vascular permeability test in the rat skin. The results show that a factor with an estimated molecular weight of 120 000 was responsible for a dose-related activity in both test systems studied. The activity of this fraction could be inhibited by various plasma kallikrein-inhibiting protease inhibitors, whereas in addition the skin response could be inhibited by pyridinolcarbamate and not by histamine- or serotonin-inhibiting drugs. From the inhibition patterns in vivo and in vitro as well as from the estimated molecular weight of the fraction, it is suggested that a plasma kallikrein-like factor might be responsible for the activities observed. We feel that further study of this fraction in rat or human serum is worthwhile in particular with respect to nephrotic conditions associated with GPA loss.
使用凝胶色谱法纯化正常大鼠血清的各组分,并使用梯度聚丙烯酰胺凝胶电泳(PAGE)分析其分子量。测试这些组分对大鼠肾组织体外肾小球多阴离子(GPA)的影响能力,同时分析其皮内注射到大鼠皮肤后在体内的血管增强能力。将这些组分与组织切片在37℃孵育2小时,随后用胶体铁对唾液蛋白进行染色,以评估体外GPA损伤情况。使用大鼠皮肤标准血管通透性试验测定增强的血管反应。结果表明,在两个研究的测试系统中,一种估计分子量为120000的因子具有剂量相关活性。该组分的活性可被多种血浆激肽释放酶抑制性蛋白酶抑制剂抑制,此外,皮肤反应可被吡啶醇氨基甲酸酯抑制,而不被组胺或5-羟色胺抑制药物抑制。从体内和体外的抑制模式以及该组分的估计分子量来看,提示一种血浆激肽释放酶样因子可能是观察到的活性的原因。我们认为,特别是对于与GPA丧失相关的肾病情况,进一步研究大鼠或人血清中的该组分是值得的。